Honda Yohsuke, Araki Motoharu, Yamawaki Masahiro, Tokuda Takahiro, Tsutumi Masakazu, Mori Shinsuke, Sakamoto Yasunari, Kobayashi Norihiro, Hirano Keisuke, Ito Yoshiaki
Saiseikai Yokohama City Eastern Hospital, Division of Cardiology, Yokohama, Japan.
J Interv Cardiol. 2018 Apr;31(2):216-222. doi: 10.1111/joic.12468. Epub 2017 Nov 28.
The aim of this study was to assess clinical benefit of the Echo-guided ProGlide technique in patients undergoing percutaneous transfemoral transcatheter aortic valve implantation (TF-TAVI).
The efficacy of the Echo-guided ProGlide technique during percutaneous TF-TAVI was not previously clarified.
A total of 121 consecutive patients who underwent percutaneous TF-TAVI at our institution between February 2014 and July 2017 were enrolled in this study. According to the introduction of this novel technique in March 2016, patients were divided into two groups (echo-guided group who underwent TAVI from March 2016 to July 2017, n = 63; not echo-guided group who underwent TAVI from February 2014 to February 2016, n = 58). The incidence of major vascular complications, defined per the Valve Academic Research Consortium-2 criteria, and ProGlide complications including acute femoral artery stenosis or occlusion and bleeding requiring any intervention.
The incidence of major vascular complication and ProGlide complication were significantly lower in the echo-guided group than in not echo-guided group (1.6% vs 17.2%, P < 0.002; 1.6% vs 15.5%, P = 0.003; respectively). Use of the Echo-guided ProGlide technique was independently associated with prevention of ProGlide complications (odds ratio, 0.11; 95% confidential interval, 0.01-0.76; P = 0.03).
This novel Echo-guided ProGlide technique was associated with a lower rate of major vascular complications, particularly ProGlide complications during percutaneous TF-TAVI.
本研究旨在评估超声引导下ProGlide技术在接受经皮股动脉经导管主动脉瓣植入术(TF-TAVI)患者中的临床获益。
先前未阐明超声引导下ProGlide技术在经皮TF-TAVI过程中的疗效。
本研究纳入了2014年2月至2017年7月在我院连续接受经皮TF-TAVI的121例患者。根据2016年3月这项新技术的引入情况,将患者分为两组(超声引导组,2016年3月至2017年7月接受TAVI,n = 63;非超声引导组,2014年2月至2016年2月接受TAVI,n = 58)。主要血管并发症的发生率根据瓣膜学术研究联盟-2标准定义,以及ProGlide并发症,包括急性股动脉狭窄或闭塞和需要任何干预的出血。
超声引导组的主要血管并发症和ProGlide并发症发生率显著低于非超声引导组(分别为1.6%对17.2%,P < 0.002;1.6%对15.5%,P = 0.003)。使用超声引导下ProGlide技术与预防ProGlide并发症独立相关(优势比,0.11;95%置信区间,0.01 - 0.76;P = 0.03)。
这种新型的超声引导下ProGlide技术与较低的主要血管并发症发生率相关,尤其是在经皮TF-TAVI期间的ProGlide并发症。